C-Reactive Protein in Prediction of Ventriculoperitoneal Shunt-Related Infection in High-Risk Patients

2013 ◽  
Vol 14 (2) ◽  
pp. 192-195 ◽  
Author(s):  
Sermkiat Lolak ◽  
Krishnapundha Bunyaratavej
Keyword(s):  
High Risk ◽  
Ventriculoperitoneal Shunt ◽  
C Reactive Protein ◽  
High Risk Patients ◽  
Reactive Protein ◽  
Risk Patients

The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease

2020 ◽  
Vol 54 (10) ◽  
pp. 1021-1029
Author(s):  
Yuani M. Roman ◽  
Adrian V. Hernandez ◽  
C. Michael White
Keyword(s):  
Cardiovascular Disease ◽  
High Risk ◽  
English Language ◽  
Atherosclerotic Cardiovascular Disease ◽  
C Reactive Protein ◽  
High Risk Patients ◽  
Reactive Protein ◽  
Risk Patients ◽  
Hs Crp ◽  
The Impact

Objective: To review the 3 anti-inflammatory drugs, canakinumab, colchicine, and methotrexate, that have been investigated in major clinical trials for treating patients with atherosclerotic cardiovascular disease (ASCVD). Data Sources: An Ovid MEDLINE literature search (1946 to February 2, 2020) was performed using search strategy [( C-reactive protein OR ASCVD OR cardiac disease OR cardiovascular disease) AND (canakinumab OR methotrexate OR Colchicine)]. Additional references were identified from the citations. Study Selection and Data Extraction: English-language studies assessing the impact of these 3 drugs on inflammation as measured by high-sensitivity C-reactive protein (hs-CRP) or the association with reducing ASCVD events were included. Data Synthesis: Canakinumab and colchicine significantly reduced ASCVD events in high-risk patients with median baseline hs-CRP levels of ~4.0 mg/L. Methotrexate was ineffective at reducing ASCVD events in high-risk patients, but their baseline hs-CRP concentrations were a median of <2 mg/L. In subgroup analyses of the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS), patients whose baseline hs-CRP was 2 to 4 mg/L had benefits from canakinumab therapy similar to those with baseline levels exceeding 4. Relevance to Patient Care and Clinical Practice: Even with the best current drug therapies, patients with underlying inflammation can benefit from the addition of both colchicine and canakinumab to further lower CV events. Given its cost, colchicine is a more attractive option. Conclusions: Patients at high risk of recurrent cardiovascular disease events with an hs-CRP of 2 mg/L or greater can reduce the occurrence of ASCVD events with canakinumab or colchicine therapy. Colchicine is the preferable option, in particular for those with myocardial infarction, given its more reasonable cost.

scholarly journals Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein

Life Sciences ◽  
2013 ◽  
Vol 92 (14-16) ◽  
pp. 845-851 ◽  
Author(s):  
Simone P. Barbosa ◽  
Lívia C. Lins ◽  
Francisco A. Fonseca ◽  
Lívia N. Matos ◽  
Ana C. Aguirre ◽  
...  
Keyword(s):  
High Risk ◽  
C Reactive Protein ◽  
High Risk Patients ◽  
Reactive Protein ◽  
Risk Patients

scholarly journals Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P4188-P4188
Author(s):  
M. C. Izar ◽  
S. P. Barbosa ◽  
L. C. Lins ◽  
C. N. Franca ◽  
L. N. De Matos ◽  
...  
Keyword(s):  
High Risk ◽  
C Reactive Protein ◽  
High Risk Patients ◽  
Reactive Protein ◽  
Risk Patients

Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: Comparison with C-reactive protein and adiponectin

Peptides ◽  
2008 ◽  
Vol 29 (4) ◽  
pp. 599-605 ◽  
Author(s):  
Hidenori Nishida ◽  
Takeshi Horio ◽  
Yoshihiko Suzuki ◽  
Yoshio Iwashima ◽  
Kei Kamide ◽  
...  
Keyword(s):  
High Risk ◽  
Cardiovascular Events ◽  
Independent Predictor ◽  
C Reactive Protein ◽  
High Risk Patients ◽  
Reactive Protein ◽  
Risk Patients

scholarly journals Exploring the value of routinely measured hematology parameters for identification of elderly patients at high risk of death at the Emergency Department

2018 ◽  
Vol 17 (4) ◽  
pp. 188-202
Author(s):  
Renuka S Bindraban ◽  
◽  
Maarten J ten Berg ◽  
Saskia Haitjema ◽  
Imo E Hoefer ◽  
...  
Keyword(s):  
Emergency Department ◽  
High Risk ◽  
Hematological Parameters ◽  
Added Value ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Risk Of Death ◽  
Laboratory Results ◽  
Risk Patients ◽  
Hematology Parameters

Of the warning scores in use for recognition of high-risk patients at the Emergency Department (ED), few incorporate laboratory results. Although hematological characteristics have shown prognostic value in small studies, large studies in elderly ED populations are lacking. We studied the association between blood cell and platelet counts and characteristics as well as C-reactive protein (CRP) at ED presentation with mortality in non-multitrauma patients ≥ 65 years. Comparison between survivors and non-survivors showed small, significant differences with AUROCs ranging between 56.6% and 65.2% for 30-day mortality. Combining parameters yielded an evident improvement (AUROC of 70.4%). Efforts should be pursued to study the added value of hematological parameters on top of clinical data when assessing patient risk.

scholarly journals The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines

2009 ◽  
Vol 55 (2) ◽  
pp. 219-228 ◽  
Author(s):  
Samia Mora ◽  
Kiran Musunuru ◽  
Roger S Blumenthal
Keyword(s):  
Cardiovascular Disease ◽  
Primary Prevention ◽  
High Risk ◽  
Statin Therapy ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Potential Implication ◽  
Reactive Protein ◽  
Risk Patients ◽  
Asymptomatic Individuals

Abstract Background: High-sensitivity C-reactive protein (hsCRP) testing is relatively inexpensive and has been shown to predict the risk of cardiovascular disease (CVD) and diabetes in multiple patient groups, including those treated with statin therapy. JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) is a recently completed large multicenter randomized clinical trial that tested whether statin therapy should be given to apparently healthy individuals with lower LDL cholesterol (LDL-C) concentrations but increased hsCRP concentrations. Content: This review discusses the literature on hsCRP in asymptomatic populations, analyzes it according to CVD and diabetes, and provides summary recommendations for the use of hsCRP in clinical practice. In this context, we highlight recent data from the landmark JUPITER trial, which demonstrated that hsCRP can be used to target high-risk patients who have typical LDL-C concentrations and no known vascular disease or diabetes and who would benefit from statin use. We also summarize evidence that among patients treated with statin therapy, achieving low hsCRP concentrations may be a clinically relevant therapeutic goal along with achieving very low LDL-C concentrations. Summary: JUPITER has demonstrated that combining hsCRP testing with traditional testing of lipids can reduce incident CVD in high-risk asymptomatic individuals by 44% and all-cause mortality by approximately 20%, extending the therapeutic use of statins for the primary prevention of CVD. Guidelines for practitioners could include testing asymptomatic individuals for increased concentrations of hsCRP in men ≥50 years and women ≥60 years when LDL-C concentrations are not increased and for whom the decision to treat with statin therapy is not otherwise clear.

Sign in / Sign up

Export Citation Format

Share Document